KNSA
Kiniksa Pharmaceuticals International Plc
NASDAQ · Healthcare · Biotechnology · BM
$90.37
+2.30%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$88.92
From 52W high−7.37%
Volume96316.00
Market cap$7.10B
P/E (TTM)63.2x
P/S (TTM)7.5x
Div yield—
Key dataNov 6, 2026
Open
$88.92
From 52W high
−7.37%
Volume
96316.00
Market cap
$7.10B
ValuationView details →
P/E (Fwd)
59.9x
EV/EBITDA
45.4x
P/E (TTM)
63.2x
RSI (14)
59.9
MomentumView details →
1D Return
+2.30%
YTD Return
+124.12%
SummaryUpdated Sep 1, 2026
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company founded in 2015 and based in Hamilton, Bermuda. The company went public in May 2018 and focuses on developing and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Kiniksa has successfully transitioned from a development-stage company to a profitable commercial enterprise, primarily driven by the success of its flagship product ARCALYST for treating recurrent pericarditis, a rare inflammatory cardiovascular condition.
Similar companies
Latest newsMore news →
Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $286.0 million and net income of $47.3 million, and forecast 2026 ARCALYST net product revenue of $1.045 billion to $1.050 billion.9d agoKiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.101d ago